Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of intratumoral EDS01 plus paclitaxel/cisplatin for cervical nodal metastases from advanced head and neck cancer
ChiCTR2000029997Phase 2Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Apr 2020
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Recombinant human endostatin adenovirus in head and neck cancer (HNC), nasopharyngeal carcinoma (NPC) and head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Complete cytoreduction of tumor lesion. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
Recombinant human endostatin adenovirus
03
Conditions
head and neck cancer (HNC)nasopharyngeal carcinoma (NPC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2000029997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029997.